Table 1 Model parameters and data sources
Parameter for the model | Base case value | Data source |
|---|---|---|
Number of participants in study | 1000 | |
Sensitivity of NPT with nasal swabs | 0.98 | Bell et al. [9] |
Specificity of NPT with nasal swabs | 0.86 | Bell et al. [9] |
Sensitivity of NPT with throat swabs | 0.76 | Davis et al. [4] |
Specificity of NPT with throat swabs | 0.97 | Davis et al. [4] |
Prevalence of influenza | 0.17 | Bell et al. [9] |
Length of stay, influenza diagnosed (days) | 5.00 | Duration of antiviral treatment |
Length of stay, influenza not diagnosed (days) | 3.00 | Av days to PCR result |
Cost of NPT test | 23.45 | Estimate |
Cost of RT-PCR | 70.00 | Estimate |
Cost of full isolation (Cost of partial isolation = cIsol/2) | 88.43 | Health Protection Scotland [14] |
Cost per dose of 75 mg oseltamivir (taken every 12 h) | 1.54 | MIMS [15] |
Cost of nosocomial infection | 2*(cOseltamivir * 2 * RxOseltamivir + cIsol*los) | NICE guidance [1] |
Number of days for oseltamivir treatment | 5.00 | MIMS [15] |
Probability of isolation if influenza detected | 1.00 | Expert opinion |
Probability of isolation if influenza not detected | 0.00 | Expert opinion |
Probability of nosocomial infection | 0.20 | Expert opinion |